Literature DB >> 21374220

Preparation of HSV-DNA and Production of Infectious Virus.

A R Maclean1.   

Abstract

This chapter deals with (1) the preparation of herpes simplex virus (HSV) virion DNA of a quality and purity suitable to be used for the generation of infectious virus, and (2) its use in the preparation of infectious virus. An important development in the understanding of virus genetics and gene products has been the ability to carry out reverse genetics. This is dependent on the ability to manipulate the genome in vitro and reconstitute infectious virus. Our understanding of DNA viruses and positive stranded RNA viruses (where DNA and RNA/cDNA, respectively, are generally infectious) is considerably greater than for negative stranded RNA viruses, where until recently, it had been impossible to generate virus.from either RNA or cDNA. Within the herpesviridae, knowledge of the function of HSV gene products is one of the more advanced owing to the relatively straightforward techniques required to generate virus from HSV-DNA, and to introduce desired mutations by cloning small parts of the genome, manipulating them, and then reintroducing the mutations by a process of cotransfection and in vivo recombination with intact virus DNA. Other α-herpesviruses, such as EHV-1 and PRV, are equally amenable to such manipulation, and knowledge of their gene products is also well advanced. In contrast, this technology is only now, and with much less success, being applied to other members of the family, such as EBV, HCMV, and VZV, and knowledge of their genetics is much less advanced. The use of cosmids to reconstitute intact virus will aid in the advance of knowledge for these viruses. For examples of uses of recombinant DNA technology, the reader is referred to other chapters (especially those on cloning and mutagenesis). I will concentrate on the techniques currently in use in my laboratory, but will also mention other techniques in use elsewhere that may be more appropriate in certain cell types.

Entities:  

Year:  1998        PMID: 21374220     DOI: 10.1385/0-89603-347-3:19

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  6 in total

1.  Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation.

Authors:  Claus-Henning Nagel; Nina Albrecht; Kristijana Milovic-Holm; Lakshmikanth Mariyanna; Britta Keyser; Bettina Abel; Britta Weseloh; Thomas G Hofmann; Martha M Eibl; Joachim Hauber
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Herpes simplex virus 1 immediate-early and early gene expression during reactivation from latency under conditions that prevent infectious virus production.

Authors:  Jean M Pesola; Jia Zhu; David M Knipe; Donald M Coen
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B.

Authors:  Benjamin Shogan; Lori Kruse; Gilbert B Mulamba; André Hu; Donald M Coen
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Nuclear egress and envelopment of herpes simplex virus capsids analyzed with dual-color fluorescence HSV1(17+).

Authors:  Claus-Henning Nagel; Katinka Döhner; Mojgan Fathollahy; Tanja Strive; Eva Maria Borst; Martin Messerle; Beate Sodeik
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

5.  Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma.

Authors:  Yong Luo; Chaolong Lin; Wenfeng Ren; Fei Ju; Zilong Xu; Huiling Liu; Zeng Yu; Jun Chen; Jun Zhang; Pingguo Liu; Chenghao Huang; Ningshao Xia
Journal:  Mol Ther Oncolytics       Date:  2019-10-01       Impact factor: 7.200

6.  Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens.

Authors:  Yong Luo; Chaolong Lin; Yidi Zou; Fei Ju; Wenfeng Ren; Yanhua Lin; Yale Wang; Xiaoxuan Huang; Huiling Liu; Zeng Yu; Pingguo Liu; Guowei Tan; Quan Yuan; Jun Zhang; Chenghao Huang; Ningshao Xia
Journal:  Oncoimmunology       Date:  2020-02-12       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.